CZ299847B6 - Použití (S,S)-reboxetinu pro výrobu léciva pro prevenci nebo lécbu chronických onemocnení - Google Patents

Použití (S,S)-reboxetinu pro výrobu léciva pro prevenci nebo lécbu chronických onemocnení Download PDF

Info

Publication number
CZ299847B6
CZ299847B6 CZ20014625A CZ20014625A CZ299847B6 CZ 299847 B6 CZ299847 B6 CZ 299847B6 CZ 20014625 A CZ20014625 A CZ 20014625A CZ 20014625 A CZ20014625 A CZ 20014625A CZ 299847 B6 CZ299847 B6 CZ 299847B6
Authority
CZ
Czechia
Prior art keywords
reboxetine
disorder
optically pure
norepinephrine
reuptake
Prior art date
Application number
CZ20014625A
Other languages
Czech (cs)
English (en)
Other versions
CZ20014625A3 (cs
Inventor
H. F. Wong@Erik
Ahmed@Saeeduddin
Clyde Marshall@Robert
McArthur@Robert
P. Taylor@Duncan
Birgerson@Lars
Cetera@Pacquale
Original Assignee
Pharmacia & Upjohn Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27495506&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CZ299847(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia & Upjohn Company filed Critical Pharmacia & Upjohn Company
Publication of CZ20014625A3 publication Critical patent/CZ20014625A3/cs
Publication of CZ299847B6 publication Critical patent/CZ299847B6/cs

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CZ20014625A 1999-07-01 2000-06-22 Použití (S,S)-reboxetinu pro výrobu léciva pro prevenci nebo lécbu chronických onemocnení CZ299847B6 (cs)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14196899P 1999-07-01 1999-07-01
US14413199P 1999-07-16 1999-07-16
US15825699P 1999-10-06 1999-10-06
US17038199P 1999-12-13 1999-12-13

Publications (2)

Publication Number Publication Date
CZ20014625A3 CZ20014625A3 (cs) 2002-08-14
CZ299847B6 true CZ299847B6 (cs) 2008-12-10

Family

ID=27495506

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ20014625A CZ299847B6 (cs) 1999-07-01 2000-06-22 Použití (S,S)-reboxetinu pro výrobu léciva pro prevenci nebo lécbu chronických onemocnení

Country Status (30)

Country Link
US (18) US6465458B1 (enExample)
EP (3) EP1196172B1 (enExample)
JP (3) JP2003503450A (enExample)
KR (5) KR100717660B1 (enExample)
CN (5) CN1205935C (enExample)
AR (1) AR035158A1 (enExample)
AT (9) ATE319453T1 (enExample)
AU (2) AU771258B2 (enExample)
BR (1) BR0012136A (enExample)
CA (2) CA2643231A1 (enExample)
CL (3) CL2008002867A1 (enExample)
CO (1) CO5190662A1 (enExample)
CZ (1) CZ299847B6 (enExample)
DE (9) DE60022917T2 (enExample)
DK (4) DK1459749T3 (enExample)
EA (6) EA008381B1 (enExample)
ES (9) ES2239311T3 (enExample)
GE (1) GEP20094798B (enExample)
HU (1) HUP0201623A3 (enExample)
IL (3) IL147246A0 (enExample)
MX (1) MXPA02000562A (enExample)
MY (1) MY137348A (enExample)
NO (4) NO20016406L (enExample)
NZ (2) NZ515885A (enExample)
PE (1) PE20010684A1 (enExample)
PL (1) PL196996B1 (enExample)
PT (5) PT1459748E (enExample)
SK (5) SK286864B6 (enExample)
TW (9) TWI294779B (enExample)
WO (1) WO2001001973A2 (enExample)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL196996B1 (pl) * 1999-07-01 2008-02-29 Upjohn Co Zastosowanie optycznie czystej (S,S)-reboksetyny lub jej dopuszczalnej farmaceutycznie soli do wytwarzania leku
TWI238062B (en) * 1999-12-01 2005-08-21 Ucb Sa A pyrrolidineacetamide derivative alone or in combination for treatment of CNS disorders
ES2253370T3 (es) 2000-04-21 2006-06-01 PHARMACIA & UPJOHN COMPANY LLC Cabergolina para el tratamiento del sindrome de fibromialgia y de fatiga cronica.
BR0110188A (pt) * 2000-04-21 2003-03-05 Upjohn Co Compostos selecionados para o tratamento de sìndromes de fibromialgia e de fadiga crÈnica
US20040048860A1 (en) * 2000-10-31 2004-03-11 Jes Olesen Use of selective noradrenaline reuptake inhibitors for the treatment of tension-type headache
PL366119A1 (en) * 2000-11-15 2005-01-24 Eli Lilly And Company Treatment of anxiety disorders
WO2002083141A1 (en) * 2001-04-17 2002-10-24 Pharmacia & Upjohn Company Treatment of fibromyalgia and chronic fatigue syndrome
US20040048874A1 (en) * 2001-05-22 2004-03-11 Bardsley Hazel Judith New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine
GB0216027D0 (en) * 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
DK1627639T3 (da) * 2001-06-19 2010-04-26 Norbert Mueller Anvendelse af COX-2-inhibitorer til behandling af affektive lidelser
US20060167074A1 (en) * 2001-06-19 2006-07-27 Norbert Muller Methods and compositions for the treatment of psychiatric disorders
US6602911B2 (en) 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
WO2003047560A1 (en) * 2001-11-30 2003-06-12 Eli Lilly And Company Use of norepinephrine reuptake inhibitors for the treatment of tic disorders
SK2442004A3 (en) * 2001-12-11 2004-12-01 Lilly Co Eli Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure
US20040102440A1 (en) * 2002-07-01 2004-05-27 Wong Erik Ho Fong Method of promoting smoking cessation
CA2475763A1 (en) * 2002-02-12 2003-08-21 Cypress Bioscience, Inc. Methods of treating attention deficit/hyperactivity disorder (adhd)
MXPA04011529A (es) * 2002-04-24 2005-08-15 Cypress Bioscience Inc Prevencion y tratamiento de trastornos somaticos funcionales, incluyendo trastornos relacionados con la tension.
EP2301537A1 (en) * 2002-05-17 2011-03-30 Duke University Zonisamide for the treatment of obesity
US7459464B2 (en) * 2002-05-30 2008-12-02 Neurosearch A/S Triple monoamine reuptake inhibitors for the treatment of chronic pain
ES2328472T3 (es) * 2002-06-17 2009-11-13 Pfizer Italia S.R.L. Sales farmaceuticas de reboxetina.
US20050226926A1 (en) 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
MY136318A (en) * 2002-07-25 2008-09-30 Pharmacia Corp Sustained-release tablet composition
MXPA05001705A (es) * 2002-08-14 2005-04-19 Pharmacia & Upjohn Co Llc Uso de reboxetina para el tratamiento de sofocos.
AU2003261245A1 (en) 2002-08-23 2004-03-11 Eli Lilly And Company Benzyl morpholine derivatives
EP1534291B1 (en) 2002-08-23 2008-11-12 Eli Lilly And Company 2-(phenylthiomethyl)- morpholine derivatives for use as selective norepinephrine reuptake inhibitors
GB0219687D0 (en) 2002-08-23 2002-10-02 Lilly Co Eli Benzyl morpholine derivatives
AU2003284005B2 (en) * 2002-10-03 2009-12-17 Forest Laboratories Holdings Limited Dosage escalation and divided daily dose of anti-depressants to treat neurological disorders
US20040152710A1 (en) * 2002-10-15 2004-08-05 Deecher Darlene Coleman Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
US7345096B2 (en) * 2002-10-15 2008-03-18 Wyeth Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
US20040180879A1 (en) * 2002-10-15 2004-09-16 Deecher Darlene Coleman Novel method of treating vasomotor symptoms
US20040204411A1 (en) * 2002-12-17 2004-10-14 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
WO2004062623A2 (en) * 2003-01-13 2004-07-29 Dynogen Pharmaceuticals, Inc. Method of treating functional bowel disorders
ES2285407T3 (es) * 2003-01-13 2007-11-16 Dynogen Pharmaceuticals Inc. Metodo para el tratamiento de nauseas, vomitos, arcadas o cualquiera de sus combinaciones.
WO2004089288A2 (en) * 2003-04-04 2004-10-21 Dynogen Pharmaceuticals, Inc. Method of treating lower urinary tract disorders
MXPA05011557A (es) 2003-04-29 2006-03-09 Orexigen Therapeutics Inc Composiciones para afectar perdida de peso.
US8158149B2 (en) * 2004-05-12 2012-04-17 Chelsea Therapeutics, Inc. Threo-DOPS controlled release formulation
WO2004100929A1 (en) 2003-05-12 2004-11-25 Synergia Pharma, Inc. Threo-dops controlled release formulation
WO2004105690A2 (en) * 2003-05-23 2004-12-09 Cypress Bioscience, Inc. Treatment of chronic pain associated with drug or radiation therapy
GB0319793D0 (en) * 2003-08-22 2003-09-24 Lilly Co Eli Pyridinylmorpholine derivatives
US20060241188A1 (en) * 2003-08-27 2006-10-26 Elililly And Company Treatment of pervasive developemental disorders with norepinephrine reuptake inhibitors
US20070010584A1 (en) * 2003-09-04 2007-01-11 Peroutka Stephen J Compositions and methods for orthostatic intolerance
MXPA06002789A (es) * 2003-09-12 2006-06-14 Pfizer Combinaciones que comprenden ligandos alfa-2-delta.
US7531543B2 (en) 2003-10-14 2009-05-12 Wyeth Phenylpiperazine cycloalkanol derivatives and methods of their use
US7365076B2 (en) 2003-10-14 2008-04-29 Wyeth Substituted aryl cycloalkanol derivatives and methods of their use
US7524846B2 (en) 2003-10-14 2009-04-28 Wyeth Arylalkyl- and cycloalkylalkyl-piperazine derivatives and methods of their use
US7402698B2 (en) 2003-10-14 2008-07-22 Wyeth Secondary amino-and cycloamino-cycloalkanol derivatives and methods of their use
US7550485B2 (en) * 2003-10-14 2009-06-23 Wyeth Substituted N-heterocycle derivatives and methods of their use
US7491723B2 (en) 2003-10-14 2009-02-17 Wyeth Alkanol and cycloalkanol-amine derivatives and methods of their use
US20050130987A1 (en) * 2003-10-14 2005-06-16 Wyeth Methods of treating vasomotor symptoms
US7419980B2 (en) 2003-10-14 2008-09-02 Wyeth Fused-aryl and heteroaryl derivatives and methods of their use
GB0326148D0 (en) 2003-11-10 2003-12-17 Lilly Co Eli Morpholine derivatives
ATE399557T1 (de) * 2003-12-12 2008-07-15 Lilly Co Eli Selektive norepinephrin-wiederaufnahmehemmer zur behandlung von hitzewallungen
EP1716126B1 (en) 2003-12-23 2009-02-25 Eli Lilly And Company Morpholine derivatives as norepinephrine reuptake inhibitors
US7517899B2 (en) * 2004-03-30 2009-04-14 Wyeth Phenylaminopropanol derivatives and methods of their use
US7414052B2 (en) 2004-03-30 2008-08-19 Wyeth Phenylaminopropanol derivatives and methods of their use
MXPA06012505A (es) * 2004-04-30 2006-12-15 Warner Lambert Co Compuestos de morfolina sustituida para el tratamiento de trastornos del sistema nervioso central.
KR100871272B1 (ko) * 2004-04-30 2008-11-28 화이자 인코포레이티드 모폴린 화합물
GB0409744D0 (en) * 2004-04-30 2004-06-09 Pfizer Ltd Novel compounds
CA2567365A1 (en) * 2004-06-09 2006-01-05 Pfizer Inc. Use of reboxetine for the treatment of pain
US7244765B2 (en) * 2004-06-25 2007-07-17 Cytokine Pharmasciences, Inc Guanylhydrazone salts, compositions, processes of making and methods of using
US20090227562A1 (en) * 2004-08-10 2009-09-10 Pfizer Inc. Combination of a Selective Noradrenaline Reuptake Unhibitor and a PDEV Inhibitor
PH12012501282A1 (en) 2004-08-13 2019-03-22 Boehringer Ingelheim Int Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
US20080261955A1 (en) * 2004-10-01 2008-10-23 Timothy Dinan Use of Pharmaceutical Compositions of Lofepramine for the Treatment of Adhd, Cfs, Fm and Depression
US20060293309A1 (en) * 2005-03-28 2006-12-28 Dynogen Pharmaceuticals, Inc. Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
EP2135603B1 (en) 2005-11-22 2013-01-02 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
US20070253994A1 (en) * 2006-04-28 2007-11-01 Medtronic, Inc. Intraspinal Drug Delivery Methods and Devices To Alleviate Chronic Pelvic Pain
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
ES2571730T3 (es) * 2006-06-28 2016-05-26 Lundbeck Na Ltd Composiciones farmacéuticas que comprenden droxidopa
JP2010508997A (ja) 2006-11-09 2010-03-25 オレキシジェン・セラピューティクス・インコーポレーテッド 減量薬を投与するための方法
AU2008226541B2 (en) 2007-03-09 2013-05-09 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of fibromyalgia
WO2008122019A1 (en) * 2007-04-02 2008-10-09 Cypress Biosciences, Inc. Improving the tolerability of both mirtazapine and reboxetine by using them in combination
NZ581391A (en) * 2007-04-30 2012-06-29 Adolor Corp Compositions of (-)-e-10-oh-nt and methods for their synthesis and use
EP2167066B1 (en) * 2007-05-07 2013-06-26 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of attention deficit disorders
US8580776B2 (en) * 2007-07-10 2013-11-12 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating neurodegenerating diseases
US20090233959A1 (en) * 2008-02-19 2009-09-17 Adolor Corporation Beloxepin and analogs for the treatment of pain
US20090233957A1 (en) * 2008-02-19 2009-09-17 Adolor Corporation (-)-beloxepin and methods for its synthesis and use
US8956642B2 (en) 2008-04-18 2015-02-17 Medtronic, Inc. Bupivacaine formulation in a polyorthoester carrier
US8475823B2 (en) 2008-04-18 2013-07-02 Medtronic, Inc. Baclofen formulation in a polyorthoester carrier
MX2010012909A (es) 2008-05-30 2011-02-25 Orexigen Therapeutics Inc Metodos para tratamiento de condiciones de grasa visceral.
ES2434250T3 (es) 2008-07-24 2013-12-16 Theravance, Inc. Compuestos de 3-(fenoxifenilmetil)pirrolidina
US20100069389A1 (en) * 2008-09-06 2010-03-18 Bionevia Pharmaceuticals, Inc. Novel forms of reboxetine
WO2010044016A1 (en) * 2008-10-17 2010-04-22 Pfizer Limited Novel uses for esreboxetine and racemic reboxetine
JP2012524098A (ja) * 2009-04-15 2012-10-11 セラヴァンス， インコーポレーテッド ３−（フェノキシピロリジン−３−イル−メチル）ヘテロアリール、３−（フェニルピロリジン−３−イルメトキシ）ヘテロアリールおよび３−（ヘテロアリールピロリジン−３−イルメトキシ）ヘテロアリール化合物
EP2454234B1 (en) 2009-07-13 2018-04-11 Theravance Biopharma R&D IP, LLC 3-phenoxymethylpyrrolidine compounds
ES2495366T3 (es) 2009-07-21 2014-09-17 Theravance, Inc. Compuestos de 3-fenoximetilpirrolidina
CA2785822C (en) 2010-01-11 2019-06-25 Orexigen Therapeutics, Inc. Methods of providing weight loss therapy in patients with major depression
US8471040B2 (en) 2010-10-11 2013-06-25 Theravance, Inc. Serotonin reuptake inhibitors
WO2012075239A1 (en) 2010-12-03 2012-06-07 Theravance, Inc. Serotonin reuptake inhibitors
JP5880913B2 (ja) 2011-05-17 2016-03-09 三郎 佐古田 パーキンソン病の体幹症状（姿勢反射異常）の治療剤
KR20200035501A (ko) 2012-06-06 2020-04-03 오렉시젠 세러퓨틱스 인크. 과체중 및 비만의 치료 방법
WO2016077724A1 (en) 2014-11-13 2016-05-19 University Of Pittsburgh - Of The Commonwealth System Of Higher Education (2-amino-4(arylamino)phenyl) carbamates
US20190381056A1 (en) 2018-06-17 2019-12-19 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
WO2021113163A1 (en) * 2019-12-03 2021-06-10 Axsome Therapeutics, Inc. Use of reboxetine to treat nervous system disorders
US20200147093A1 (en) 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
US11020402B2 (en) 2018-10-15 2021-06-01 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
EP3693020A1 (en) * 2019-02-08 2020-08-12 Burmaster International Group GmbH Potassium enriched topical formulations for pain relief and sleep aid
CA3163505A1 (en) * 2019-12-03 2021-06-10 Axsome Therapeutics, Inc. Use of reboxetine to treat nervous system disorders

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2167407A (en) * 1984-11-22 1986-05-29 Erba Farmitalia Enantiomers of phenoxy derivatives of benzyl morpholine and salts thereof
WO1999015177A1 (en) * 1997-09-23 1999-04-01 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
WO1999015176A1 (en) * 1997-09-23 1999-04-01 Eli Lilly And Company Treatment of oppositional defiant disorder
WO1999015163A1 (en) * 1997-09-23 1999-04-01 Eli Lilly And Company Treatment of conduct disorder

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3797494A (en) 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3996934A (en) 1971-08-09 1976-12-14 Alza Corporation Medical bandage
US3742951A (en) 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US4031894A (en) 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
IL56369A (en) * 1978-01-20 1984-05-31 Erba Farmitalia Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
US4465458A (en) * 1980-03-19 1984-08-14 Matsushita Electric Industrial Co., Ltd. Apparatus for burning liquid fuel equipped with heating-type fuel vaporizer
GB8419683D0 (en) 1984-08-02 1984-09-05 Erba Farmitalia 3-substituted derivatives of 1-amino-2-hydroxy-propane
US4596807A (en) 1985-03-26 1986-06-24 Serotonin Industries Of Charleston Method and compositions for controlling pain, depression and sedation
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
PH30083A (en) 1991-02-25 1996-12-27 Lilly Co Eli Treatment of lower urinary tract disorders
US5281624A (en) 1991-09-27 1994-01-25 Eli Lilly And Company N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof
US5192751A (en) 1992-07-24 1993-03-09 Eli Lilly And Company Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence
TW344661B (en) 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
IL111786A0 (en) 1993-12-01 1995-01-24 Max Planck Gesellschaft Methods of promoting the survival and differentiation of subclasses of cholinergic and serotonergic neurons using fibroblast growth factor-5
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
ZA958725B (en) 1994-10-20 1997-04-16 Lilly Co Eli Treatment of disorders with duloxetine
WO1997035586A1 (en) 1996-03-25 1997-10-02 Eli Lilly And Company Method for treating pain
EP0906104A4 (en) 1996-03-25 2003-12-10 Lilly Co Eli PAIN TREATMENT PROCESS
US5914333A (en) * 1996-07-31 1999-06-22 Novo Nordisk A/S Treatment of psychotic disorders
US6290986B1 (en) * 1996-10-24 2001-09-18 Pharmaceutical Applications Associates, Llc Method and composition for transdermal administration of pharmacologic agents
WO1999011208A1 (en) 1997-08-28 1999-03-11 Williams C Donald Method and composition for transdermal administration of pharmacologic agents
US6572880B2 (en) * 1996-10-24 2003-06-03 Pharmaceutical Applications Associates Llc Methods and transdermal compositions for pain relief
US20020015713A1 (en) * 1996-10-24 2002-02-07 Murdock Robert W. Methods and transdermal compositions for pain relief
US6479074B2 (en) * 1996-10-24 2002-11-12 Pharmaceutical Applications Associates Llc Methods and transdermal compositions for pain relief
DE59600683D1 (de) 1996-11-27 1998-11-19 Pfleger R Chem Fab Verwendung von Trospiumchlorid zur Herstellung eines Arzneimittels zur Behandlung von Blasenkrankheiten
KR20000057548A (ko) 1996-12-13 2000-09-25 알프레드 엘. 미첼슨 광학적 전송물질 및 결합재
AU6966998A (en) 1997-04-11 1998-11-11 Eli Lilly And Company Composition for treating pain
US5942530A (en) 1997-08-28 1999-08-24 Eli Lilly And Company Method for treating pain
US6622036B1 (en) * 2000-02-09 2003-09-16 Cns Response Method for classifying and treating physiologic brain imbalances using quantitative EEG
US6066643A (en) 1997-10-17 2000-05-23 Eli Lilly And Company Potentiation of pharmaceuticals
BR9909478A (pt) 1998-04-09 2000-12-19 Upjohn Co Novos tratamentos para vários distúrbios do sistema nervoso
US6586427B2 (en) * 1998-04-09 2003-07-01 Pharmacia & Upjohn Company Treatments for nervous disorders
IT1305322B1 (it) * 1998-04-23 2001-05-04 Pharmacia & Upjohn Spa Uso di reboxetina per il trattamento di disturbi nervosi
HUP0101341A3 (en) * 1998-05-08 2006-07-28 Upjohn Co New drug combinations
CN1331576A (zh) 1998-06-29 2002-01-16 药品应用协会有限公司 用于缓解疼痛的方法和经皮组合物
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
PL196996B1 (pl) 1999-07-01 2008-02-29 Upjohn Co Zastosowanie optycznie czystej (S,S)-reboksetyny lub jej dopuszczalnej farmaceutycznie soli do wytwarzania leku
GB2355191A (en) * 1999-10-12 2001-04-18 Laxdale Ltd Combination formulations for fatigue, head injury and strokes
SE9904750D0 (sv) 1999-12-23 1999-12-23 Pharmacia & Upjohn Ab New formulation, use and method
CN1396829A (zh) * 2000-02-24 2003-02-12 法玛西雅厄普约翰美国公司 新的药物联合形式
US20050096349A1 (en) * 2003-11-03 2005-05-05 University Of Florida Methods to prevent or ameliorate medication-, procedure-or stress-induced cognitive and speech dysfunction and methods to optimize cognitive and speech functioning

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2167407A (en) * 1984-11-22 1986-05-29 Erba Farmitalia Enantiomers of phenoxy derivatives of benzyl morpholine and salts thereof
WO1999015177A1 (en) * 1997-09-23 1999-04-01 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
WO1999015176A1 (en) * 1997-09-23 1999-04-01 Eli Lilly And Company Treatment of oppositional defiant disorder
WO1999015163A1 (en) * 1997-09-23 1999-04-01 Eli Lilly And Company Treatment of conduct disorder

Also Published As

Publication number Publication date
US20020128173A1 (en) 2002-09-12
NO20091158L (no) 2002-02-19
ES2247572T3 (es) 2006-03-01
CA2375908A1 (en) 2001-01-11
DE60026627T2 (de) 2007-02-01
KR20090087135A (ko) 2009-08-14
SK286668B6 (sk) 2009-03-05
MY137348A (en) 2009-01-30
KR20050053799A (ko) 2005-06-08
US20080096890A1 (en) 2008-04-24
ATE305307T1 (de) 2005-10-15
DE60022692T2 (de) 2006-06-22
EA008381B1 (ru) 2007-04-27
ES2246485T3 (es) 2006-02-16
SK286667B6 (sk) 2009-03-05
US6610690B2 (en) 2003-08-26
EP2087892A2 (en) 2009-08-12
US6987107B2 (en) 2006-01-17
SK286104B6 (sk) 2008-03-05
ATE296634T1 (de) 2005-06-15
US7317011B2 (en) 2008-01-08
EA011094B1 (ru) 2008-12-30
CN1379672A (zh) 2002-11-13
TW200914027A (en) 2009-04-01
US20020107249A1 (en) 2002-08-08
WO2001001973A3 (en) 2002-01-17
EA006652B1 (ru) 2006-02-24
US20020061910A1 (en) 2002-05-23
US20090247528A1 (en) 2009-10-01
ES2258010T3 (es) 2006-08-16
DE60026704T2 (de) 2006-10-19
US20060135520A1 (en) 2006-06-22
DE60022916D1 (de) 2006-02-09
ES2239311T3 (es) 2005-09-16
PT1632234E (pt) 2007-07-09
US20020086864A1 (en) 2002-07-04
US20040058925A1 (en) 2004-03-25
ES2246487T3 (es) 2006-02-16
US7338953B2 (en) 2008-03-04
KR20090087134A (ko) 2009-08-14
DE60035232T2 (de) 2008-02-14
TWI298254B (en) 2008-07-01
EA005029B1 (ru) 2004-10-28
SK286669B6 (sk) 2009-03-05
TW200407146A (en) 2004-05-16
MXPA02000562A (es) 2002-07-02
IL187512A0 (en) 2008-06-05
NO20091159L (no) 2002-02-19
TW200607510A (en) 2006-03-01
US20080103146A1 (en) 2008-05-01
PL196996B1 (pl) 2008-02-29
ATE364386T1 (de) 2007-07-15
JP2003503450A (ja) 2003-01-28
HUP0201623A2 (en) 2002-09-28
CN1660108A (zh) 2005-08-31
ATE292971T1 (de) 2005-04-15
KR100704319B1 (ko) 2007-04-09
PT1196172E (pt) 2006-05-31
AU771258B2 (en) 2004-03-18
TW200920378A (en) 2009-05-16
PL352252A1 (en) 2003-08-11
US20060264436A1 (en) 2006-11-23
ATE319453T1 (de) 2006-03-15
PT1459750E (pt) 2005-08-31
NO20016406D0 (no) 2001-12-28
EA200801806A1 (ru) 2008-12-30
EA200700232A1 (ru) 2007-06-29
EP1196172A2 (en) 2002-04-17
ATE305788T1 (de) 2005-10-15
JP2006143749A (ja) 2006-06-08
CL2008002866A1 (es) 2009-01-09
DE60022692D1 (de) 2005-10-20
DE60020613D1 (de) 2005-07-07
EP1196172B1 (en) 2006-03-15
EA200400589A1 (ru) 2004-12-30
EA200200111A1 (ru) 2002-06-27
US20060142289A1 (en) 2006-06-29
HK1049630A1 (en) 2003-05-23
CN1660110A (zh) 2005-08-31
US20060128705A1 (en) 2006-06-15
JP2006321815A (ja) 2006-11-30
KR100935277B1 (ko) 2010-01-06
DK1459749T3 (da) 2006-01-09
CO5190662A1 (es) 2002-08-29
US6703389B2 (en) 2004-03-09
TW200607512A (en) 2006-03-01
KR20020015363A (ko) 2002-02-27
TWI293250B (en) 2008-02-11
ATE320257T1 (de) 2006-04-15
SK286864B6 (sk) 2009-06-05
SK19382001A3 (sk) 2002-07-02
DE60022917T2 (de) 2006-06-29
DE60022916T2 (de) 2006-07-06
CN1289090C (zh) 2006-12-13
DE60026627D1 (de) 2006-05-04
DK1196172T3 (da) 2006-06-19
US7723334B2 (en) 2010-05-25
US6465458B1 (en) 2002-10-15
DE60026704D1 (de) 2006-05-11
DE60035232D1 (de) 2007-07-26
CN1660109A (zh) 2005-08-31
TWI298255B (en) 2008-07-01
US20080103147A1 (en) 2008-05-01
KR20060099544A (ko) 2006-09-19
CN1660111A (zh) 2005-08-31
US7276503B2 (en) 2007-10-02
DE60019473D1 (de) 2005-05-19
HUP0201623A3 (en) 2004-12-28
US20040147614A1 (en) 2004-07-29
IL187513A0 (en) 2008-06-05
ATE305306T1 (de) 2005-10-15
PT1459751E (pt) 2005-11-30
TW200607511A (en) 2006-03-01
DE60020613T2 (de) 2006-03-16
NO20016406L (no) 2002-02-19
AR035158A1 (es) 2004-05-05
EA200501496A1 (ru) 2006-06-30
GEP20094798B (en) 2009-10-26
DK1459750T3 (da) 2005-08-15
PE20010684A1 (es) 2001-06-24
KR100948757B1 (ko) 2010-03-23
EP2090312A1 (en) 2009-08-19
EP2087892A3 (en) 2009-09-30
HK1076723A1 (en) 2006-01-27
BR0012136A (pt) 2002-06-11
AU2004202096B2 (en) 2005-10-20
NZ515885A (en) 2004-08-27
DE60023043T2 (de) 2006-06-14
US20080103145A1 (en) 2008-05-01
DE60019473T2 (de) 2006-02-23
ES2246488T3 (es) 2006-02-16
ATE304358T1 (de) 2005-09-15
US6642235B2 (en) 2003-11-04
WO2001001973A2 (en) 2001-01-11
AU5633700A (en) 2001-01-22
CL2008002867A1 (es) 2009-01-09
NZ533243A (en) 2005-12-23
CA2375908C (en) 2006-05-30
ES2258251T3 (es) 2006-08-16
DE60023043D1 (de) 2006-02-16
IL147246A0 (en) 2002-08-14
TWI245631B (en) 2005-12-21
ES2242175T3 (es) 2005-11-01
WO2001001973A8 (en) 2001-05-17
DE60022917D1 (de) 2006-02-09
CZ20014625A3 (cs) 2002-08-14
DK1632234T3 (da) 2007-09-17
TW200607509A (en) 2006-03-01
KR100717660B1 (ko) 2007-05-15
TWI294779B (en) 2008-03-21
CN1205935C (zh) 2005-06-15
PT1459748E (pt) 2005-08-31
TW200922594A (en) 2009-06-01
ES2285645T3 (es) 2007-11-16
NO20091168L (no) 2002-02-19
EA200801805A1 (ru) 2008-12-30
CA2643231A1 (en) 2001-01-11
AU2004202096A1 (en) 2004-06-10
CL2008002868A1 (es) 2009-01-09
US20060135521A1 (en) 2006-06-22
US20030040464A1 (en) 2003-02-27
US7241762B2 (en) 2007-07-10

Similar Documents

Publication Publication Date Title
CZ299847B6 (cs) Použití (S,S)-reboxetinu pro výrobu léciva pro prevenci nebo lécbu chronických onemocnení
EP1459751B1 (en) (S,S)-reboxetine for treating migraine headaches
PL197981B1 (pl) Zastosowanie optycznie czystej (S,S)-reboksetyny lub jej dopuszczalnej farmaceutycznie soli do wytwarzania leku
PL197982B1 (pl) Zastosowanie optycznie czystej (S,S)-reboksetyny lub jej dopuszczalnej farmaceutycznie soli do wytwarzania leku
PL197984B1 (pl) Zastosowanie optycznie czystej (S,S)-reboksetyny lub jej dopuszczalnej farmaceutycznie soli do wytwarzania leku

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of fee

Effective date: 20100622